Morgan Stanley Remains Sidelined on Teva Pharma (TEVA) Following Study

Morgan Stanley reiterated an Equalweight rating and $19.00 price target on Teva Pharma (NYSE: TEVA) following a chronic cluster headache study. Fremanezumab missed on the chronic cluster headache study. Morgan Stanley is maintaining fremanezumab revenue estimates which excludes cluster.

Based on conversations with the company, Teva remains unclear of the approval/filing path for cluster headache. In the case where Teva succeeds on episodic cluster headache study, Teva is still uncertain if they will require another successful Phase 3 trial.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $23.76 yesterday.

You May Also Be Interested In

• Stifel Upgrades Barry Callebaut AG (BARN:SW) (BYCBF) to Buy
• B.Riley Starts Okeanis Eco Tankers Corp (ECO) at Buy, 'solid competitive advantage'
• Oppenheimer Upgrades Avalo Therapeutics (AVTX) to Outperform following AVTX-009 acquisition